Advagene Biopharma Co (ROCO:6709) Other Financing: NT$0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6709 Advagene Biopharma Co Ltd ROCO:6709
36 GF Score
Price NT$24.15
! 2 Warning Signs
View Full Analysis

What is Advagene Biopharma Co Other Financing?

Advagene Biopharma Co ROCO:6709 -0.82% 36 Other Financing is NT$0.00 Mil as of Dec. 2025. GuruFocus rates ROCO:6709 with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

Advagene Biopharma Co's Other Financing for the six months ended in Dec. 2025 was NT$0.00 Mil.

Advagene Biopharma Co's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.00 Mil.

Advagene Biopharma Co Other Financing Historical Data

* Premium members only.

The historical data trend for Advagene Biopharma Co's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advagene Biopharma Co Other Financing Chart

Advagene Biopharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Advagene Biopharma Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.31 0.00 150.00 0.00 0.00
ROCO:6709
36GF Score
Advagene Biopharma Co Ltd ROCO:6709
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Advagene Biopharma Co Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of NT$0.00 Mil mean?
Advagene Biopharma Co (ROCO:6709) has a Other Financing of NT$0.00 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Advagene Biopharma Co and its competitors.
Is Advagene Biopharma Co's Other Financing too high?
Advagene Biopharma Co's current Other Financing is NT$0.00 Mil. Overall, Advagene Biopharma Co has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Advagene Biopharma Co's Other Financing compare to VRTX and REGN?
Advagene Biopharma Co's Other Financing of NT$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Advagene Biopharma Co and its competitors. Advagene Biopharma Co's current Other Financing is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advagene Biopharma Co stock overvalued right now?
Advagene Biopharma Co (ROCO:6709) has a current Other Financing of NT$0.00 Mil. The current Other Financing is NT$0.00 Mil. Advagene Biopharma Co's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Advagene Biopharma Co (ROCO:6709), the current Other Financing is NT$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advagene Biopharma Co Business Description

Address Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114
Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based biotechnology company. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray seasonal flu vaccine, nasal spray COVID-19 vaccine, Immunotherapy for COVID-19, Respiratory Allergy Immunotherapy - Allergic Rhinitis and Asthma ,and other vaccines.
36GF Score

Get the complete analysis for ROCO:6709

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.15
Price